After hours: November 27 at 6:56 PM EST Loading Chart for GSK ...

Teva Pharmaceutical Industries Ltd. ADR-0.12% $18.68B ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some ...

Vaccine makers face a demand cliff as coronavirus vaccines wane, but these stocks are more than meets the eye.

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents, the ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 40,410.96 Crore) operating in Pharmaceuticals sector. GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue ...

Emma Walmsley, CEO of GSK leading the keynote at the FT Live Global Pharma and Biotech Summit in London. Credit: Jenna Philpott / GlobalData. Following Donald Trump’s re-election as the 47 th ...